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Abstract
Background: Muscle atrophy is the shrinkage of muscle fibers that are largely maintained by a
balance of protein synthesis and degradation. Imbalances in protein synthesis and degradation
are observed in different muscle atrophy disorders such as cancer cachexia and disuse. These
forms of muscle atrophy produce distinct wasting pathologies that are influenced by biological
sex. Activin receptor type-2B (ACVR2B) and Growth factor receptor-bound protein 10
(GRB10) have been identified as genes that potentially regulate muscle mass while also
displaying sexually dimorphic differences. Purpose: To examine the influence of ACVR2B and
GRB10 throughout the development of cancer cachexia and disuse-induced atrophy in male and
female mice. Methods: Lewis Lung Carcinoma (LLC) was injected into the hind flank of male
and female C57BL6/J mice at 8 weeks of age. Tumors were allowed to develop for 1, 2, 3, or 4
weeks and were compared to a PBS control. Disuse-induced male and female C57BL6/J mice
were hindlimb unloaded for 24 hours, 48 hours, 72 hours, and 168 hours and were compared to
cage control mice. RT-qPCR was used to measure mRNA content of ACVR2B and GRB10 of
the gastrocnemius muscle. Results: LLC female mice had ~35% lower ACVR2B mRNA
content compared to PBS control with a ~40% and ~30% lower content at LT and HT compared
to 2-week LLC animals (p<0.05). LLC male ACVR2B mRNA contents were significantly lower
by ~48%, ~56%, and ~36% at one, two, and four weeks, respectively, of tumor-bearing
compared to PBS control mice (p=0.0006). No significant differences were observed in GRB10
mRNA content in LLC female mice across all cohorts. GRB10 mRNA content in LLC males
was significantly lower by ~41% after one week of tumor implantation compared to LLC PBS
control mice (p=0.0094).

ACVR2B mRNA content in HU female mice was not significantly

different across all cohorts (p=0.192). HU males displayed a ~two-fold lower ACVR2B mRNA

content after 3 days compared to cage control mice (p=0.0233) and 7 days of unloading
(p=0.015). GRB10 mRNA content in HU males was significantly lower at 2 and 3 days with a
~51% lower content compared to control mice with also a ~two-fold decrease compared to 7
days of hindlimb unloading. Conclusions: ACVR2B and GRB10 content displayed differential
responses during cancer cachexia and disuse-induced muscle atrophy that varied by sex. Data
suggests that ACVR2B and GRB10 play a greater role in males during muscle atrophy than
compared to females. Future experiments incorporating additional muscle groups are warranted
to better understand the pathways of ACVR2B and GRB10 and their influence between sexes
during cancer cachexia and disuse.
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I. Literature Review
Muscle Wasting Overview
Muscle atrophy is defined as the shrinkage of muscle fibers due to the loss of contractile
proteins and organelles.1 Skeletal muscle mass is largely maintained by a balance between
protein synthesis and degradation contributing to overall muscle mass.2 When an imbalance of
protein synthesis and degradation occur, muscle atrophy can be observed as seen in disorders
such as cancer and disuse.3, 4 Cancer cachexia and muscle disuse produce distinct wasting
pathologies and understanding the mechanisms and pathways associated with each can aid in the
development of preventative and possibly, curative treatments.2 Muscle atrophy is further
associated with muscle weakness and fatigue contributing to a reduced quality of life.5
Therefore, it is clinically important to further investigate the mechanisms in different pathologies
that contribute to muscle atrophy and the preservation of muscle mass.
Looking specifically at cancer cachexia and disuse-induced muscle wasting, I will
investigate the different patterns of wasting between male and female mice with a specific focus
of the genes associated with muscle growth such as Activin receptor type-2B (ACVR2B) and
Growth factor receptor-bound protein 10 (GRB10). Because recent evidence demonstrates sexrelated differences in response to different types of muscle atrophies such as cancer cachexia and
disuse-induced,6 it is of great benefit to further investigate these differences as increased
understanding can advance knowledge and therapeutic strategies in muscle atrophy. These genes
have previously been shown to be significant regulators of muscle mass with prevalent
dimorphic expression but have not been systematically investigated to determine their roles in
muscle homeostasis during disuse and cancer cachexia-induced muscle atrophy.7 This observed
sex-related difference in expression will be further built upon by examining how cancer cachexia
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and disuse-induced muscle atrophy influences the expression of ACVR2B and GRB10 in male
and female mice.

Cancer Cachexia
Cancer cachexia is defined as the decrease of skeletal muscle and adipose tissue masses,
with the development of cancer, that cannot be reversed by nutritional support alone.8 Cancer
cachexia contributes to the death of an estimated 2 million people worldwide each year.5, 9 It is
estimated that 1.8 million Americans will be diagnosed with cancer in the year 2020 while an
estimate 606,520 will die from the disease.10 Cachexia is estimated to be the primary cause of
death for approximately 30% of cancer patients.11 In addition, cancer cachexia is often
associated with pancreatic, esophageal, lung, liver, stomach, and bowel cancer.12
There are multiple mechanisms involved in the development of cancer cachexia, many
including physiologic responses driven by inflammation and pro-inflammatory cytokine activity
which has been associated with muscle wasting.3 A favored atrophy of Type II muscle fibers is
observed with cancer cachexia displaying a fast-to-slow fiber type shift.13 To date, there are no
reversible treatments of cancer cachexia and therapy remains focused on supplying nutritional
support while researchers investigate approaches that can target and reduce overactivation of cell
injury and inflammation.12

Disuse-induced Atrophy
Prolonged muscle disuse is an inducible form of muscle wasting. This type of atrophy
can be observed with prolonged bed rest, casting, immobilization, and limb unloading.6, 14
Disuse can lead to a reduction in muscle mass, fiber size, strength, and function with the extent
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varying on the length of disuse and the specific muscle.14 Disuse atrophy is fiber type
dependent, however, in contrast with cancer cachexia, disuse presents with a greater
susceptibility of oxidative, Type I muscle fibers.6 A greater percentage loss of fiber crosssectional area is observed in Type I muscle fibers than compared to Type II muscle fibers
affecting specific muscles differently based on fiber type composition.4 Studies have shown that
skeletal muscle mass and strength can decrease 6-24% following various types of disuse.15
These values are dependent on the muscle type and extent of unloading.4 Unlike cancer
cachexia, disuse atrophy does not display an inflammatory action.6
There are many proposed pathways contributing to muscle atrophy observed with disuse.
Molecular signal changes in pathways such as the Protein kinase B (also known as AKT)Mechanistic target of rapamycin (mTOR) pathway and Myostatin pathway display skeletal
muscle protein adaptations that occur through disuse. Activation of AKT via phosphorylation
activates mTOR kinase leading to the activation of Ribosomal protein S6 kinase beta-1
(p70S6K), a translation initiation factor involved in regulating protein synthesis, remaining as an
essential part of muscle protein synthesis.15-17 AKT-mTOR pathway is not activated in disuse
conditions leading to muscle atrophy.15 While there is a decrease in basal protein synthesis,
there is limited evidence of protein degradation observed in humans.4 Treatments to combat
disuse muscle atrophy remain minimal due to a lack of understanding of the molecular and
cellular mechanisms responsible for atrophy. Therefore, further investigation on regulation of
muscle protein turnover is needed to effectively prevent muscle wasting caused via disuse.
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Muscle Sex Differences
Characteristics of muscle atrophy varies depending on the cause of wasting as well as
biological sex. Sex hormones play a significant role in muscle homeostasis ranging from
anabolism, regeneration, and inflammation, sometimes acting as protective factors.18 Males
largely express testosterone that actively promotes muscular regeneration and protein synthesis
through androgen receptor signaling.19 Females, having lower levels of testosterone, express
estrogen which has a protective effect by mitigating inflammation in skeletal muscle.18 Other
studies have demonstrated a potential protective effect from female sex hormones in disuse
atrophy.20 Because of these sex differences and varying hormonal profiles, it is important to
investigate the influence sex can have on different atrophy conditions. Cancer cachexia and
disuse atrophy have markedly different characteristics associated with each which is influenced
by biological sex.21 While there are various sex-differences that influence muscle phenotype,
function, and regulation,6 little investigation has focused on the biological sex differences and
mechanisms during wasting and warrants further investigation.21
Looking at the muscle composition between sexes, women have a larger relative
composition of Type I muscle fibers and depend more on oxidative metabolism compared to
males.6 Conversely, males have a larger ratio of Type II glycolytic muscle fibers and a greater
muscle mass.6 This difference in muscle fiber type composition influences the ways males and
females atrophy during disuse and cancer cachexia due to the two types of wasting differential
responses.
Cancer cachexia favors the atrophy of Type II glycolytic muscle fibers and displays a
fast-to-slow muscle fiber type switch.13 Males experiencing cancer cachexia have been shown to
lose a greater percent of body weight, rapidly losing muscle and fat, compared to females whose
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fat mass declines initially but lose muscle more gradually.18 Overall, females appear to be more
protected from the inflammation induced muscle wasting which occurs during cancer cachexia
when compared to males who have greater muscle losses.6
Disuse-induced favors atrophy of oxidative myofibers.21 Muscles predominantly
composed of slow twitch fibers, such as postural muscles, are highly susceptible to disuse and
can display fiber shifts towards fast glycolytic phenotypes.15 Because muscle composition varies
between the sexes, it is important to consider sex when investigating disuse atrophy. As
previously stated, females have a relatively larger composition of Type I oxidative muscle
fibers.6 Research has shown that atrophying skeletal muscle has an increase in oxidative stress
and that estradiol can act as both a membrane stabilizer and antioxidant.20 Few studies have
specifically focused on the potential influence sex differences can have on disuse atrophy, but
research has shown that women lose muscle faster compared to males.6 Women have also been
shown to display a greater loss of strength in isometric and concentric contractions compared to
males after short-term immobilization.20 Despite a previous study showing men and women
having similar decreases in cross-sectional area after disuse-induced, men retained a greater
degree of specific strength compared to females.20
While sex differences have been observed through disuse-induced atrophy, it is not clear
whether these differences can be attributed to the favorable atrophy of Type I oxidative muscle
fibers that are more abundant in females, or if there are other differences in muscle physiology
between sexes.6 Understanding the wasting characteristics of cancer cachexia and disuseinduced and the differences that are present between sexes create the foundation for
understanding the potential dimorphic expression of ACVR2B and GRB10.
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ACVR2B
ACVR2B is an activin and part of the TGF Beta family.22 It is a protein coding gene and
encodes a myostatin receptor involved in growth factor pathways known to regulate muscle
mass.7 Activin type II receptors are capable of binding myostatin, a negative regulator of muscle
growth that blocks myogenic development, and other TGF Beta family members.23 TGF Beta
family receptors and ligands control progenitor activation and muscle growth formation.24
Previous research has shown increased muscle mass and promoted skeletal muscle growth in
mice following the administration of soluble ACVR2B.25 The soluble form of ACVR2B leads to
the suppression of myostatin.24 Muscle mass increases of up to 60% have been observed in wildtype mice following soluble ACVR2B administration.23 Further research and better
understanding of ACVR2B may be clinically beneficial in the prevention of muscle atrophy and
can aid in treatments of degenerative myopathies, like cancer cachexia. Pathways involving
ACVR2B are yet to be fully understood whether they act primarily upon myofibers or target
additional cell types.24
The binding of myostatin is proposed to signal through two activin receptors, ACVR2A
and ACVR2B.26 Activin type 1 receptors are activated and phosphorylated through the binding
of myostatin to ACVR2B which leads to intracellular signaling of receptor-regulated proteins,
Smad2 and Smad3.25 Smad2, Smad3, and Smad4 are required for myostatin-induced
transcription.27 Administration of soluble ACVR2B has shown to inhibit muscle and adipose
wasting in cachexia by targeting myostatin-family ligands.28
Inhibition of myostatin binding has previously been shown to be a therapeutic approach
to preserving muscle mass in cancer cachexia.28 A proposed mechanism of muscle wasting
observed in cachexia is increased signaling of activin receptor ligands.29 Blocking of these
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ligands and their receptors can prevent muscle atrophy as well as increase of muscle mass.
Soluble ACVR2B produced an increase of muscle mass by 23-40% in a study performed by
Benny Klimek et al.28 While this study effectively showed that ACVR2B promotes muscle
preservation in cancer cachexia, the protective effect may be due to other myostatin targets and
the underlying mechanisms are yet to be fully uncovered. Other studies have shown that
blocking of activin receptor ligands can improve survival of cancer with improved limb and
respiratory muscle mass.29 In addition, Huot et al30 demonstrated the complete preservation of
cardiac and muscle function as well as preservation of adipose tissue, bone, and skeletal muscle
in tumor hosts receiving ACVR2B/Fc. While there is previous research focused on ACVR2B’s
protective effect of muscle mass throughout cancer cachexia, research is not as prevalent on its
impact in disuse-induced and potential differences in expression between sexes. Studies focused
on cancer cachexia have briefly mentioned ACVR2B’s protective effect on muscle mass in other
myopathies often including disuse.
When examining the expression of ACVR2B between sexes, to my knowledge, one study
has observed to be expressed at 1.6-fold greater in women compared to men using quantitative
RT-PCR.7 Difference in the expression of ACVR2B between sexes is scarce but few
associations have been observed in regard to cancer treatments incorporating both sexes. A
study on liver cancer investigating levels of ACVR2B-AS1 showing that liver cancer specimens
contained significantly elevated levels of ACVR2B-AS1 and that women with higher levels had
shorter relapse-free survival compared to those with lower ACVR2B-AS1 levels.31 This study
further showed that ACVR2B could be a beneficial therapeutic target in cancer treatment and
prognosis. Further investigation is warranted to understand sexual dimorphic expression of
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ACVR2B in cancer cachexia and disuse for the preservation of muscle mass and advanced
treatment opportunities.

GRB10
Growth factor receptor-bound protein 10 is an adapter protein that interacts with the
insulin receptor by binding to and suppressing signaling.32 It is involved with many tyrosinephosphorylated growth factor receptors and is highly expressed in muscle, pancreas, and adipose
tissues that involve glucose metabolism and insulin action.33 Variations in GRB10 expression
alter insulin receptor protein levels.32 GRB10 negatively regulates insulin signaling with the
inhibition of insulin receptor kinase activity by facilitating degradation of the receptor. By
controlling the receptor, activation of growth factors can be regulated.34
GRB10 has been shown to play an important role in the regulation of muscle size and
muscle metabolism.33 Studies involving mice with the loss of GRB10 resulted in increased
signaling of the insulin receptor in muscle tissue and increased glucose uptake.35 GRB10 knock
out mice have also shown hyperplasia of muscle cells.33 A study performed by Smith et al35
compared muscle and adipose mass from birth to one-year of male and female wild-type mice
and disrupted GRB10 mice. This study showed that male and female GRB10 mice were
approximately 13% heavier with reduced adiposity at six months compared to wild-type
littermates.35
In addition to insulin receptor signaling, GRB10 is also a substrate for mTOR complex
1.36 Edick et al.36 characterized the function of GRB10 and its regulation of mTORC1 in human
muscle. This study proposed that mTORC1 controls phosphatidylinositide 3-kinase (PI3K)
signaling by GRB10 through alteration of insulin receptor abundance. The PI3K/Akt pathway
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plays great significance for metabolic actions of insulin including glucose uptake and glycogen
synthesis in skeletal muscle. GRB10 silenced myotube showed increased insulin responsiveness
with enhanced insulin-induced PI3K/Akt signaling with a higher abundance of the insulin
receptor.36 Emerging research into cancer cachexia has focused on the influence and
contribution of mTOR and mTOR inhibitors.37 GRB10 stabilizes mTORC1 which participates
in cell proliferation and survival. With GRB10’s role in regulating mTORC1 and its negative
feedback on PI3K/Akt signaling not yet being fully established, research into the expression of
GRB10 in cancer can contribute further insight.
Differences in insulin receptor gene expression has been observed to be higher in women
by a 3-fold increase.7 Because GRB10 expression can restrain IGF-1 signaling, Welle et al7
proposes that a greater GRB10 expression may contribute to sex differences in muscularity. This
hypothesis is supported from Smith et al35 where GRB10 knockout mice exhibited increased
muscularity. Similar to ACVR2B, literature of sexual dimorphic expression of GRB10 is limited
and warrants further investigation. In addition, the influence GRB10 has on skeletal muscle
makes it an important contender towards investigating changes in expression that may occur
during muscle atrophy in cancer cachexia and disuse.

Purpose
Considering the potential interplay with muscle growth mechanism and the limited
knowledge regarding the roles of ACVR2B and GRB10 during muscle atrophies between males
and females, the purpose of this work is to better understand biological sex differences in
ACVR2B and GRB10 expression during cancer cachexia and disuse-induced muscle atrophy.
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This study will aid in improved treatment and preventative therapies to counteract the
progression of muscle atrophy.

Objectives for Data Analysis
•

Describe muscle atrophy characteristics observed between disuse-induced and cancer
cachexia

•

Describe difference of muscle wasting in males versus females during disuse-induced and
cancer cachexia samples

•

Assess differences in expression of ACVR2B and GRB10 during disuse-induced and
cancer cachexia samples

•

Determine differences in expression of ACVR2B and GRB10 in males and females

•

Further experiments may be pursued as dictated by data outcomes

II. Methods
Animal experiments for this proposal were previously approved by the University of
Arkansas Institutional Animal Care and Use Committee and performed by Dr. Greene’s
laboratory group. My work does not involve direct use of research animals but is limited to
analysis of muscle tissue samples previously collected. This thesis involves analysis of collected
tissue samples from two different models of muscle atrophy; hindlimb suspension for induceddisuse atrophy and Lewis Lung Carcinoma (LLC) implantation for induced cancer cachexia.
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Animals and Intervention
The mice utilized for this study were a cohort of male and female C57BL/6J mice
purchased from Jackson Laboratories (Bar Harbor, ME, USA). All animal experiments were
performed at the University of Arkansas in Fayetteville, Arkansas and have been approved by
the Institutional Animal Care and Use Committees of the University of Arkansas. These animals
were housed to meet the requirements for hindlimb suspension as well as being placed in a
temperature-controlled environment maintained on a 12:12 h light-dark cycle. The mice
received ad libitum access to normal rodent chow and water. The mice utilized for induced
cancer cachexia received LLC implantation at 8 weeks in the hind flank. I did not personal
perform animal work in this thesis; all animal work was previously performed and I am solely
working with tissue analyses.

Hindlimb Suspension
Induced muscle atrophy of the skeletal muscle was produced by hindlimb suspension as
previously described.38-40 Prior to hindlimb suspension, mice were acclimatized to handling by
researchers for one week before being subjected to seven days of suspension. Animals’ tails
were first sterilized using ethanol wipes followed by iodine swabsticks. After which, tails were
coated with benzoin to increase adhesiveness of the tail. Appropriate size of athletic tape was
then wrapped around the base of the animals’ tail and a small stainless-steel hook was then
connected to the athletic tape and adjusted to allow normal blood circulation. Fishing string was
then utilized to connect between the hook and a custom designed pulley system to allow for
unloading of the hindlimb legs, allowing only forelimbs to have contact with the cage floor with
a suspension angle of 30-45 degrees. The unloading system involved a single rod that reaches

12
across the cage allowing access to all areas but limiting contact with cage walls to prevent
potential hindlimb loading. The cage floor was fitted with grid wire with only a small amount of
bedding to prevent hindlimb loading from mounded up bedding. Animals were monitored daily
to ensure unloading of hindlimbs as well as signs of tail necrosis or distress. With the mice
being suspended for seven days to induce disuse atrophy, the bedding materials were not
replaced through the course of the experiment. Disuse was allowed to develop over a time
course to create the following experimental groups: cage control, 24 hours, 48 hours, 72 hours,
and 168 hours of disuse. The length of disuse has been shown to induce disuse atrophy in both
male and female animal models.41-44

Lewis Lung Carcinoma Cell Culture and Implantation
Lewis lung carcinoma cells (ATCC CRL-164) were used for this project. LLC cell
culture and harvest were prepared as previously described by Brown et al.45 Briefly, these cells
were plated in 250 mL culture flasks in DMEM with 10% fetal bovine serum supplemented with
1% penicillin and streptomycin. Upon confluency, cells were trypsinized, suspended, counted,
and diluted in PBS for implantation. At 8 weeks of age, mice were implanted with LLC (1 x 106
cells in 100 uL of PBS) subcutaneously in the hind flank where the tumor was allowed to
develop for 1-4 weeks in separate cohorts of animal. A control group was given an equal volume
of PBS at 8 weeks of age while also aged-matched with 4 weeks of tumor bearing mice. At the
time of harvest, mice were 12 weeks in age. This method has been widely used to induce cancer
cachexia and inducing cachectic phenotype.45-47
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Tissue Collection and Sample Preparation
After the suspension and cancer-induced cachectic periods, animals were anesthetized
under isoflurane. Tissue samples of the plantaris, gastrocnemius, soleus, extensor digitorum
longus; EDL, tibialis anterior; TA, heart, tumor, lungs, spleen, epididymal fat, and plasma were
collected, and mice were humanely euthanized while under anesthesia. Tissue sample weights
were recorded and snap-frozen in liquid nitrogen. Tissues were stored at -80°C for further
analyzation. For the purpose of this thesis, the gastrocnemius muscles are the only tissue sample
being analyzed.

RNA isolation, cDNA synthesis, and qualitative real-time qPCR
Frozen gastrocnemius muscle samples were powdered, and 20 mg of samples were
suspended in 1 mL of TRIzol reagent and then homogenized using a Polytron for ~5 seconds for
five times. These samples were transferred into a 1.5 mL microtube on ice and 200 μL of
chloroform was added. After 15 minutes, the samples were vortexed and centrifuged for 25
minutes. The supernatant liquid was removed and placed in a new tube where equal amounts of
70% of Diethyl Pyrocabonate (DEPC) treated ethanol was added as the sample was loaded into a
RNeasy column. An RNA isolation kit (K145002; Invitrogen, Carlsbad, CA, USA), was used
for RNA isolation. 30 uL of DNase treated RNA was collected and the purity of the RNA was
verified by fluorometry using 260/280 nm ratios read on a Bio-Tek Power Wave XC microplate
reader (BioTek Instruments Inc., Winooski, VT, USA) with Take3 microvolume plate and Gen5
software. Subsequently, using VILO Superscript reagent (11755050; Invitrogen, Carlsbad, CA,
USA), 1 μg of RNA was reverse-transcribed into cDNA and diluted to 1:100 (10 ng/μL) through
the process. Real-time polymerase chain reaction (PCR) was performed on the sample with the
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use of TaqMan probe reagent, Step-One real-time RT-PCR instrumentation (Applied
BioSystems, Foster City, CA, USA), and QuantStudio 3 Flex real‐time RT‐PCR instrumentation
(Applied BioSystems, Foster City, CA). Ct values were analyzed following the manufacturer’s
protocols of 4 minutes of incubations, 45 cycles of denaturation, and annealing and extension at
95 °C, 60 °C, and 72°C. Target TaqMan probes for ACVR2B (Mm00431664) and GRB10
(Mm01180443) were purchased from Applied Biosystems (Life Technologies). The final gene
expressions were calculated using the ΔΔCT method and the relative quantification was
calculated as 2- ΔΔCT as described previously.48 As a loading control, 18s Ct values did not differ
between groups within each experiment.

Statistical Analysis
A One-way ANOVA will be used as the global analysis for each dependent variable.
Where significant F-ratio is found, statistical differences among means were determined by
Tukey’s post hoc test. The comparison-wise error rate, α, is set at 0.05 for all statistical tests.
All data will be analyzed using the Statistical Analysis System (SAS, version 9.3, Cary, NC,
USA) and data expression as mean ± Standard error of the mean (SEM).

III. Results
Induced muscle atrophy by cancer cachexia and hindlimb unloading
Phenotypic characteristics of mice following induced cancer cachexia and hindlimb
unloading have been previously reported.45, 46, 49 Following tumor implantation, tissue wet
weights of the gastrocnemius muscle were ~12% lower in 4-week male tumor-bearing mice
compared to control mice (p<0.05)45 while female gastrocnemius muscle were ~8% lower in 1-
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week females compared to controls (p<0.05).50 After hindlimb unloading, males and females
both showed lower body and lower-limb muscle weights (p<0.05).49 Lower overall muscle
weights in females were significant after 24 hours of unloading while this effect was absent in
males.49

ACVR2B and GRB10 mRNA Content in Lewis Lung carcinoma male and female mice
ACVR2B and GRB10 mRNA contents were not significantly different between
biological sexes for PBS control LLC mice (p>0.05, Figure 1B & 1D). In LLC induced
cachexia, female mice had a lower significant mRNA content of ~35% in ACVR2B in the lowtumor cohort compared to female PBS control mice. Females were also ~40% and ~30% lower
at LT and HT compared to 2-week LLC animals, respectively (p<0.05, Figure 2C). LLC male
ACVR2B mRNA contents were significantly lower by ~48%, ~56%, and ~36% at one, two, and
four weeks, respectively, of tumor-bearing compared to PBS control mice (p=0.0006, Figure
2G). Despite a significant main effect (p=0.0429), no significant pairwise differences between
groups were observed in GRB10 mRNA content in tumor-bearing female mice (Figure 2D). In
LLC males, GRB10 mRNA content was significantly lower by ~41% after one week of tumor
implantation compared to LLC PBS control mice (p=0.0094, Figure 2H).

ACVR2B and GRB10 mRNA Content in hindlimb unloading male and female mice
Cage control mice for hindlimb unloading demonstrated no significant differences
between biological sexes in either ACVR2B or GRB10 mRNA contents (p>0.05, Figure 1A &
1C). ACVR2B mRNA content was not significantly different in hindlimb unloading female
mice across cohorts (p=0.192, Figure 2A). However, there were significant differences in males
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with a ~two-fold lower ACVR2B mRNA content at 3 days compared to cage control mice
(p=0.0233) and 7 days of unloading (p=0.015, Figure 2E). In females, GRB10 mRNA content
with hindlimb unloading was not significantly different compared to cage controls (p>0.05,
Figure 2B) although there were statistical differences observed elsewhere. HU female mice after
one day of hindlimb unloading were ~2-fold lower in GRB10 mRNA content compared to 3
(p=0.0142) and 7 days (p=0.0364) of hindlimb unloading. GRB10 mRNA content in male mice
was significantly lower at 2 days and 3 days with ~51% lower content compared to control mice
while also ~two-fold lower compared to 7 days of hindlimb unloading mice (Figure 2F).

IV. Discussion
In the present study, I sought to define ACVR2B and GRB10 responses to distinct forms
of muscle atrophy, cancer cachexia and disuse, in male compared to female mice to identify
potential roles of these muscle mass-associated proteins across muscle wasting. The results
demonstrate ACVR2B and GRB10 are differentially regulated between sexes during the
development of muscle atrophy induced by cancer cachexia and disuse. In addition, both
ACVR2B and GRB10 appear to play a greater role in males during muscle atrophy compared to
their female counterparts. Although molecular or phenotypical alterations of skeletal muscle
have been well reported in muscle atrophy, to my knowledge, no studies have investigated
molecular mechanisms involved in ACVR2B and GRB10 throughout cancer cachexia and
disuse-induced wasting, nor while investigating potential sex differences. Therefore, major
findings of the current project emphasize the importance of biological sex as well as a necessity
for further investigations on ACVR2B and GRB10 in muscle atrophy.

17
Male and Female ACVR2B Content Response Differences in HU & LLC Mice
The investigation of ACVR2B mRNA content in response to cancer cachexia and disuseinduced muscle atrophy between sexes, to my knowledge, has rarely been explored. In this
project, ACVR2B mRNA content showed significant differences across cohorts of LLC cancer
cachexia and HU disuse-induced atrophy in a sex-dependent manner. In fact, although we did
not find a statistical significance in ACVR2B content in female mice during the development of
hindlimb unloading-induced muscle atrophy, that of ACVR2B was significantly lower in LLCmediated tumor-bearing female mice, indicating ACVR2B may play an important role in
development of cancer-induced atrophy. Comparable to these results, a Chopard et al. showed
no changes in ACVR2B mRNA content in women after two weeks of human immobilization.51
Although a direct comparison between humans and rodents is limited, current data suggests
ACVR2B may not be associated with disuse-induced muscle atrophy in females.
Differing from females, HU male mice showed lower mRNA content in ACVR2B after 2
and 3 days of unloading with only 3 days being significant. A previous study examined
ACVR2B mRNA content in the quadriceps of male participants after 2 weeks of immobilization
and 6 weeks of rehabilitation. The ACVR2B content was not influenced by immobilization nor
by rehabilitation.52 Although there were no ACVR2B content changes observed in immobilized
humans, the loss seen in HU male mice could be due to the use of different muscles analyzed.
After 2 weeks of immobilization, the quadriceps muscle had a ~5% decrease in muscle mass
while the gastrocnemius in mice had a ~12% loss potentially indicating that alterations to
ACVR2B mRNA content may necessitate a more severe muscle loss.49, 52
Unlike HU mice, male and female LLC mice both had significantly reduced ACVR2B
mRNA content. Female mice had a lower ACVR2B content in the low-tumor cohort (late-stage
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cancer) compared to PBS control whereas ACVR2B content in males was lower in all tumorimplanted mice cohorts. Females have been shown to be more protected from inflammationinduced muscle wasting and to lose muscle mass more gradually during cancer cachexia which
may contribute to the differences observed between males and females.6, 18
LLC male mice displayed significantly low ACVR2B content (~2 folds) during the
development and progression of cancer cachexia. Interestingly, lower ACVR2B content was
observed in early-stage cancer, which remained lower until marked muscle wasting occurs (latestage cancer), indicating lower ACVR2B mRNA content may serve as an early biomarker for
muscle wasting in male cancer cachexia. Collectively, altered mRNA content of ACVR2B
seems to play an important role in cancer-mediated muscle wasting to a greater extent in male
mice.
There has been much investigation into the therapeutic work of soluble ACVR2B in the
treatment and prevention of cancer cachexia.7, 53-55 To my knowledge, no studies have
specifically examined the response of ACVR2B during cancer without the administration of
soluble ACVR2B or knockout. Therefore, further studies on the ACVR2B mechanism in a
cancer-mediated environment are warranted to unravel ambiguous muscle wasting mechanisms
during the development of cancer cachexia.
Although ACVR2B has rarely been studied in cancer cachexia, a few interesting findings
of ACVR2B in response to different forms of muscle atrophy have been reported. For example,
a prior study by Yaden et al. investigated the effects of overexpressing activin A and the direct
consequences on muscle tissue.56 Indeed, overexpression of activin A produced a 52% reduction
in muscle mass and produced more pronounced decreases than observed with myostatin
overexpression.56 Differences in muscle mass did not relate to mRNA levels in the current study
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and further investigation of protein levels may be warranted. The continuation of ACVR2B’s
role during muscle atrophy is encouraged to be explored alongside myostatin as differences in
myostatin activity between males and females could be related to differences in proteins that
process, bind, and signal transduce myostatin.7

Male and Female GRB10 Content Response Differences in HU & LLC Mice
Significantly less GRB10 content was observed in male and female hindlimb (HU) mice.
While both had significant decreases in GRB10 content during HU, females demonstrated lower
GBR10 content within 24 hours with levels returning to baseline, however, in males this
reduction was shown after 2 days following HU before returning to baseline. Similar to this
pattern, females experiencing disuse have shown significantly lower muscle weights after 1 day
of unloading, unlike males where lower muscle mass is seen at 2 days of unloading.49 Although
males and females have similar decreases in cross-sectional area during disuse, research has
shown females lose muscle faster with males retaining a greater specific strength.6, 20 With
females experiencing the onset of disuse sooner compared to males while correspondingly
displaying an earlier decrease of GRB10 mRNA content, the onset of muscle loss is marked by a
loss in GRB10 mRNA content as also seen in males.
Male LLC mice displayed an initial loss in GRB10 mRNA content after one week of
tumor implantation while this effect was not observed in females nor beyond one week in males.
Changes in muscle mass can significantly affect glucose homeostasis and metabolic health, as
seen with muscle atrophy, and is associated with decreased insulin sensitivity.15, 58 As females
have increased insulin receptor gene expression and are more protected against inflammation-
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induced muscle atrophy, these factors could support the limited differences observed in GRB10
mRNA content during cancer cachexia in female mice.6, 7
GRB10 promotes cell proliferation and cell survival.57 Overexpression has been
observed to result in growth retardation and insulin resistance.57 Looking at short-term muscle
disuse, skeletal muscle has been shown to be insulin resistant with the response differing across
subjects.59 The mechanisms regulating disuse-induced insulin resistance between populations
are not yet known59 but due to GRB10’s influence of binding and modulating the insulin
receptor, decreases in muscle mass and muscle atrophy could explain decreases in GRB10
content during cancer cachexia and disuse-induced atrophy.36 Investigation of GRB10 content
throughout cancer cachexia and disuse-induced wasting is limited as well as knowledge of its
role in muscle outside of the insulin signaling pathway and further exploration of GRB10’s
influence in muscle atrophy is encouraged.58

Species Difference of Humans and Mice
The application of mice modeling for human health studies has been widely and
extensively used for cancer and disuse studies.60 While mice models have ethical and practical
advantages, there are fundamental differences between species in regard to human disease
phenotypes.60, 61 Although limitations exist, cross-species comparisons at the molecular level are
feasible and insights on the degree of conservation between humans and mice have further
developed.62
There are many biological processes and genetic elements conserved between humans
and mice.62 Mice models can replicate processes within a disease but may not account for all the
physiological changes to occur throughout humans.63 Divergences and phenotypic differences
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between species may result in weakly correlated responses between the two species possibly
accounting for the differences of the result observed.62 While mice studies are extremely
beneficial, it is important to consider the species differences that may occur on the molecular and
transcriptional level when applying to human comparisons.

Vastus Lateralis and Gastrocnemius Fiber Type
It is essential to consider what particular mouse muscles most similarly represent human
muscle wasting myopathies as skeletal muscles are dissimilarly affected by varying wasting
pathologies.61 Human and mouse skeletal muscle profiles vary by muscle type with the soleus
muscle of the mouse being identified to most closely resemble the molecular expression of
human skeletal muscle for both control and disease human tissue.60, 61 For this thesis, the
gastrocnemius was the sole muscle studied. Had the same muscle been studied for humans and
mice, results may have been different. Previous studies have displayed similar atrophic changes
of the gastrocnemius and vastus lateralis muscle of humans during sarcopenia but comparisons
for mice have not been reported.64
The vastus lateralis is a well-studied muscle in human studies due to its mixed fiber type
composition and accessibility.65 For both males and females, the vastus lateralis contains
approximately 42% type I fibers, 35% type IIA fibers, and 23% type IIB fibers.65 Prior research
has also reported the vastus lateralis encompassing 32% slow-twitch fibers.66 Sex differences
have been observed for fiber size with males having larger cross-sectional areas compared to
females by 14%, 28%, and 56% for type I, IIA, and IIB fibers, respectively.65 The
gastrocnemius muscle of C57BL6J mice are predominantly type II fibers.67 In humans, the
gastrocnemius has been described as containing 50% slow-twitch fibers.66 Due to the influence
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of fiber type composition on the wasting characteristics of cancer cachexia and disuse-induced
wasting in males and females, it is important to take into consideration the difference between
the vastus lateralis and gastrocnemius muscle.
While the vastus lateralis and gastrocnemius muscle are both characterized as
predominantly fast-twitch fibers, the use of different muscle groups could account for the lack of
basal sexual dimorphic expression observed. Others who are interested in the potential sexual
dimorphism of ACVR2B and GRB10 throughout cancer cachexia and disuse-induced wasting
are encouraged to examine and compare further muscle groups.

V. Conclusion
In this study, ACVR2B and GRB10 mRNA content in male and female mice
experiencing cancer cachexia and disuse-induced muscle atrophy were assessed and ACVR2B
and GRB10 are dimorphically regulated between sexes during the progression of muscle atrophy
by induced cancer cachexia and disuse. Based on my data, ACVR2B content was less during
cancer cachexia for both male and female mice while having a larger influence and effect in male
mice. Current data suggests ACVR2B may not be associated with disuse-induced muscle atrophy
in females but displays a significant decrease in males after 3 days of unloading. Females are
also shown to have stable GRB10 mRNA content during cancer cachexia with males displaying
an initial loss after 1 week with a return to baseline. Male and female mice both experienced a
loss in GBR10 mRNA content during disuse with females displaying a faster initial loss than
compared to males. This data provides information to help combat cancer cachexia and disuseinduced muscle atrophy. With the limited knowledge surrounding ACVR2B and GRB10 content
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responses throughout cancer cachexia and disuse-induced wasting, further investigation can aid
in improved treatments and understanding of these associated pathways during muscle atrophy.
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Figure 1. Baseline control comparison of ACVR2B and GRB10 mRNA content between males
and females. (A) ACVR2B in HU controls, (B) ACVR2B in LLC controls, (C) GRB10 in HU
controls, (D) GRB10 in LLC controls.
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Figure 2. Comparison of mRNA content of ACVR2B and GRB10 during the progression of
hindlimb unloading (HU) and cancer cachexia (LLC) of the gastrocnemius muscle in male and
female mice. (A) ACVR2B in HU females, (B) GRB10 in HU females, (C) ACVR2B in LLC
females, (D) GRB10 in LLC females, (E) ACVR2B in HU males, (F) GRB10 in HU males (G)
ACVR2B in LLC males, (H) GRB10 in LLC Male. Different lettering denotes statistical
significance between groups, alpha set at p<0.05.
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The Institutional Animal Care and Use Committee (IACUC) has APPROVED your
protocol 15065: "Mitochondrial Degeneration in the Onset of Cancer-Cachexia
Induced Muscle Atrophy" you may begin work immediately
In granting its approval, the IACUC has approved only the information provided. Should
there be any further changes to the protocol during the research, please notify the IACUC
in writing (via the Modification form) prior to initiating the changes. If the study period is
expected to extend beyond Jan 1, 2018 you must submit a newly drafted protocol
prior to that date to avoid any interruption. By policy the IACUC cannot approve a study for
more than 3 years at a time.
The IACUC appreciates your cooperation in complying with University and Federal
guidelines involving animal subjects.

CNC/aem
cc: Animal Welfare Veterinarian
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4/12/2018

To:
Fr:
Date:
Subject:
Expiration Date:

vpredweb.uark.edu/iacuc-webapp/mods/letter.php?ID=1251&PROTOCOL=18111

Nicholas Greene
Craig Coon
April 12th, 2018
IACUC Approval
April 5th, 2021

The Institutional Animal Care and Use Committee (IACUC) has APPROVED your protocol # 18111: Mitochondrial
degeneration in the development of cancer-induced muscle loss in female mice.

18
11
1

In granting its approval, the IACUC has approved only the information provided. Should there be any further changes to the
protocol during the research, please notify the IACUC in writing (via the Modification form) prior to initiating the changes. If
the study period is expected to extend beyond April 5th, 2021 you must submit a newly drafted protocol prior to that date to
avoid any interruption. By policy the IACUC cannot approve a study for more than 3 years at a time.
The following individuals are approved to work on this study: Nicholas Greene, Tyrone Washington, Megan Rosa, and
Wesley Haynie. Please submit personnel additions to this protocol via the modification form prior to their start of work.
The IACUC appreciates your cooperation in complying with University and Federal guidelines involving animal subjects.
CNC/tmp

http://vpredweb.uark.edu/iacuc-webapp/mods/letter.php?ID=1251&PROTOCOL=18111
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